ODYSSEY GROUP INTL INC News

Odyssey Health, Inc. Strengthens Balance Sheet With $8.7 Million in Net Equity

LAS VEGAS, NV / ACCESSWIRE / March 27, 2024 / Odyssey Health, Inc. (OTCQB:ODYY), formerly Odyssey Group International, Inc., (the "Company") a company focused on developing unique, life-enhancing medi

AccesswireMar 27 08:30 ET

Oragenics Completes Acquisition of Odyssey Health's Neurological Assets

Oragenics, Inc. (NYSE American: OGEN) announces it has completed its previously announced acquisition of assets related to Odyssey Health, Inc.'s (OTCQB: ODYY) ("Odyssey") proprietary neurological drug therapies and technologies.

OragenicsJan 2 00:00 ET

Odyssey Health Gains Shareholder Approval for Asset Sale With Oragenics

Seeking AlphaDec 12, 2023 09:32 ET

Odyssey Health, Inc, Selects Syneos Health to Support Investigational New Drug Application for Treatment of Concussion

LAS VEGAS, NV / ACCESSWIRE / November 16, 2023 / Odyssey Health, Inc. (OTCQB:ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, ha

AccesswireNov 16, 2023 08:30 ET

Odyssey Health, Inc. to Provide Company Update and Webcast for Shareholders

LAS VEGAS, NV / ACCESSWIRE / November 15, 2023 / Odyssey Health, Inc. (OTCQB:ODYY), formerly Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products,

AccesswireNov 15, 2023 12:00 ET

Odyssey Health, Inc. Provides Update on Asset Purchase Agreement With Oragenics, Inc.

LAS VEGAS, NV / ACCESSWIRE / October 18, 2023 / Odyssey Health, Inc. (OTCQB:ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products is p

AccesswireOct 18, 2023 08:30 ET

Oragenics to Acquire Certain Assets of Odyssey Health

Seeking AlphaOct 5, 2023 06:51 ET

Oragenics: Odyssey to Retain Other Assets, Operations >OGEN ODYY

Oragenics: Odyssey to Retain Other Assets, Operations >OGEN ODYY

Dow JonesOct 5, 2023 06:31 ET

Oragenics to Pay $1 Million Cash, 8 Million Series F Convertible Preferred Shares >OGEN

Oragenics to Pay $1 Million Cash, 8 Million Series F Convertible Preferred Shares >OGEN

Dow JonesOct 5, 2023 06:31 ET

Oragenics To Acquire Odyssey Health's Neurological Drug Technology Pipeline Including Concussion Drug Candidate >OGEN ODYY

Oragenics To Acquire Odyssey Health's Neurological Drug Technology Pipeline Including Concussion Drug Candidate >OGEN ODYY

Dow JonesOct 5, 2023 06:30 ET

Odyssey Health Inc. Begins Trading on the OTCQB

LAS VEGAS, NV / ACCESSWIRE / October 4, 2023 / Odyssey Health, Inc. (formerly known as Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), is a medical device and pharmaceutic

AccesswireOct 4, 2023 08:30 ET

Odyssey Health Completes Phase I Human Clinical Trial for Concussion Drug, Preparing for Phase II

Seeking AlphaDec 19, 2022 08:57 ET

Odyssey Health, Inc. Provides a Year End Update on Company and Corporate Outlook for 2023

Las Vegas, Nevada, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing life-enhancing medical products, today

GlobeNewswireDec 19, 2022 08:36 ET

Odyssey Health, Inc. Provides Update on Company and the Progress of Concussion Drug Development

Las Vegas, Nevada, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical product

GlobeNewswireNov 23, 2022 08:35 ET

Odyssey Health, Inc. Schedules Annual Meeting of Stockholders

Las Vegas, Nevada, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc. (the "Company" or "Odyssey"), a medical technology company focused on d

GlobeNewswireNov 15, 2022 08:07 ET

Odyssey Health, Inc. Provides Recap on Concussion Drug Development

Las Vegas, Nevada, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical product

GlobeNewswireOct 6, 2022 08:36 ET

Odyssey Health, Inc. Makes Statement Regarding Its Concussion Drug Development Program

Las Vegas Nevada, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., (the "Company" "Odyssey") a company focused on developing a unique dru

GlobeNewswireSep 30, 2022 18:30 ET

Odyssey Health Rises 11% on Completing Phase 1 Trial of Concussion Treatment

Odyssey Health (OTCPK:ODYY) said it had completed the study of all cohorts for its Phase I Single Ascending Dosing and Multiple Ascending Dosing clinical trial of PRV-002, its drug to treat concussion

Seeking AlphaSep 28, 2022 11:35 ET

Odyssey Health Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial, Cohort II

Las Vegas, NV, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products,

GlobeNewswireSep 13, 2022 08:07 ET

Odyssey Health Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial

Las Vegas, NV, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, t

GlobeNewswireAug 18, 2022 08:10 ET